Saltar al contenido
Merck

Modeling atrial fibrosis in vitro-Generation and characterization of a novel human atrial fibroblast cell line.

FEBS open bio (2020-05-19)
Stephan R Künzel, Johanna S E Rausch, Charlotte Schäffer, Maximilian Hoffmann, Karolina Künzel, Erik Klapproth, Theresa Kant, Natalie Herzog, Jan-Heiner Küpper, Kristina Lorenz, Svenja Dudek, Ramona Emig, Ursula Ravens, Eva A Rog-Zielinska, Rémi Peyronnet, Ali El-Armouche
RESUMEN

Atrial fibrillation (AF) is regularly accompanied by cardiac fibrosis and concomitant heart failure. Due to the heterogeneous nature and complexity of fibrosis, the knowledge about the underlying mechanisms is limited, which prevents effective pharmacotherapy. A deeper understanding of cardiac fibroblasts is essential to meet this need. We previously described phenotypic and functional differences between atrial fibroblasts from patients in sinus rhythm and with AF. Herein, we established and characterized a novel human atrial fibroblast line, which displays typical fibroblast morphology and function comparable to primary cells but with improved proliferation capacity and low spontaneous myofibroblast differentiation. These traits make our model suitable for the study of fibrosis mechanisms and for drug screening aimed at developing effective antifibrotic pharmacotherapy.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anti-Mouse IgG (Fab specific)–Peroxidase antibody produced in goat, affinity isolated antibody, buffered aqueous solution